Myriad Genetics Inc (MYGN)

Myriad Genetics Inc. (MYGN) is a leading molecular diagnostic company headquartered in Salt Lake City, Utah, USA. Started in 1991, they're dedicated to helping patients make better-informed health decisions and improving their quality of life. The corporation uses the power of innovative technology and precise analysis to revolutionize patient care. Offering internationally recognized brands in molecular, pharmacogenomics and personalized medicine as well as several testing services, MYGN remains a pioneer in the autopsy field.

Their commitment to saving lives and reducing the economic burden of disease on families and society has been their driving force. Myriad Genetics Inc. spearheaded the discovery of the Breast Cancer genes BRCA1 and BRCA2, and designed the first-ever genetic tests for hereditary breast and ovarian cancers. This was a significant breakthrough in personalized medicine, and their hereditary cancer tests (myRisk) are now renowned.

Besides cancer, MYGN's genetic testing extends to the areas of preventive care, neurological disorders, autoimmune diseases, and psychiatric diseases. Their products include EndoPredict, a test that aids doctors in determining the best treatment for patients with breast cancer, and Prolaris, a prostate cancer prognostic test.

In addition to diagnostics, MYGN’s preventive business line focuses on preventive care. They believe in an anticipatory healthcare model wherein diseases are predicted and prevented before they manifest. Through their personalized medicine approach, they aim to tailor treatments based on a patient’s genetic makeup, making therapy more efficient and minimizing side effects.

MYGN's technology leverages next-generation sequencing, affording an extensive analysis of multiple genes at once, at lower costs, and in a significantly shorter amount of time. This capability helps in detecting numerous types of genetic abnormalities which may lead to disease.

Moreover, Myriad Genetics Inc. is not just a standalone corporation but a network of collaborations. They partner with advocacy organizations, academic institutions, healthcare providers, and pharmaceutical and biotech firms world-wide to advance their research and testing capabilities.

While Myriad Genetics Inc. is primarily based in the United States, they have a strong international presence, with subsidiaries in Canada, France, Germany, Japan, Spain, Switzerland, and the United Kingdom.

This corporation's core mission lies in making a difference in patient’s lives through the transformation and innovation of molecular diagnostic tests, ultimately leading to personalized treatment plans. It’s continually contributing to cutting-edge science and is on the frontier of creating a world where disease is a thing of the past.